# Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses

> **NCT00228163** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 147 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** teriflunomide (HMR1726)

## Key facts

- **NCT ID:** NCT00228163
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-01
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2015-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00228163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00228163, "Long Term Safety and Efficacy of Teriflunomide (HMR1726) in Multiple Sclerosis With Relapses". Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/clinical/NCT00228163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*